Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Group 1 - Mural Oncology plc is a clinical-stage immuno-oncology company focused on developing engineered therapies targeting cytokine pathways [1][2] - The company's lead candidate, nemvaleukin alfa, is in potentially registrational trials for platinum-resistant ovarian cancer and mucosal melanoma, with results expected in late Q1/early Q2 and Q2 of 2025, respectively [2] - CEO Caroline Loew, Ph.D., will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, at 3:10 p.m. ET, with a live webcast available [1]